Characteristics of patients with MM with or without documented C1As
| Variable . | With C1As . | Without C1As . | P . | ||
|---|---|---|---|---|---|
| No. . | % . | No. . | % . | ||
| No. of patients | 844 | 2734 | |||
| Median age (IQR), y | 69 (62-77) | 68 (60-76) | .002 | ||
| Female | 406 | 48.1 | 1237 | 45.2 | .150 |
| Race/ethnicity | .496 | ||||
| Non-Hispanic white | 493 | 58.4 | 1656 | 60.6 | |
| Non-Hispanic African American | 131 | 15.5 | 437 | 15.9 | |
| Hispanic | 65 | 7.7 | 183 | 6.7 | |
| Other | 75 | 8.9 | 241 | 8.8 | |
| Missing | 80 | 9.5 | 217 | 7.9 | |
| Practice type | .511 | ||||
| Academic | 80 | 9.5 | 239 | 8.7 | |
| Community | 764 | 90.5 | 2495 | 91.3 | |
| M-protein type | <.001 | ||||
| IgG | 386 | 49.2 | 1511 | 58.8 | |
| IgA | 219 | 27.9 | 505 | 19.7 | |
| Light chain | 171 | 21.8 | 515 | 20.1 | |
| Other | 9 | 1.1 | 37 | 1.4 | |
| Missing | 59 | 7 | 166 | 6.1 | |
| R-ISS stage | <.001 | ||||
| I | 140 | 16.6 | 435 | 15.9 | |
| II | 129 | 15.3 | 437 | 15.9 | |
| III | 148 | 17.5 | 322 | 11.8 | |
| Missing | 427 | 50.6 | 1540 | 56.3 | |
| ECOG PS | .903 | ||||
| 0-2 | 534 | 63.3 | 1713 | 62.6 | |
| 3-4 | 22 | 2.6 | 78 | 2.8 | |
| Missing | 288 | 34.1 | 943 | 34.5 | |
| HRCA | |||||
| Any HRCA | 227 | 26.9 | 376 | 13.8 | <.001 |
| del(17 p) | 121 | 14.3 | 231 | 8.4 | <.001 |
| t(4;14) | 87 | 10.3 | 130 | 4.8 | <.001 |
| t(14;16) | 41 | 4.9 | 47 | 1.7 | <.001 |
| Non-HRCA | |||||
| del(13q) | 414 | 49.1 | 768 | 28.1 | <.001 |
| t(11;14) | 78 | 9.2 | 411 | 15 | <.001 |
| First-line therapy | <.001 | ||||
| PI + IMiD combination | 342 | 40.5 | 916 | 33.5 | |
| PI-based | 151 | 17.9 | 615 | 22.5 | |
| IMiD-based | 284 | 33.6 | 871 | 31.9 | |
| Other | 67 | 7.9 | 332 | 12.1 | |
| ASCT | 215 | 25.5 | 768 | 28.1 | .140 |
| Variable . | With C1As . | Without C1As . | P . | ||
|---|---|---|---|---|---|
| No. . | % . | No. . | % . | ||
| No. of patients | 844 | 2734 | |||
| Median age (IQR), y | 69 (62-77) | 68 (60-76) | .002 | ||
| Female | 406 | 48.1 | 1237 | 45.2 | .150 |
| Race/ethnicity | .496 | ||||
| Non-Hispanic white | 493 | 58.4 | 1656 | 60.6 | |
| Non-Hispanic African American | 131 | 15.5 | 437 | 15.9 | |
| Hispanic | 65 | 7.7 | 183 | 6.7 | |
| Other | 75 | 8.9 | 241 | 8.8 | |
| Missing | 80 | 9.5 | 217 | 7.9 | |
| Practice type | .511 | ||||
| Academic | 80 | 9.5 | 239 | 8.7 | |
| Community | 764 | 90.5 | 2495 | 91.3 | |
| M-protein type | <.001 | ||||
| IgG | 386 | 49.2 | 1511 | 58.8 | |
| IgA | 219 | 27.9 | 505 | 19.7 | |
| Light chain | 171 | 21.8 | 515 | 20.1 | |
| Other | 9 | 1.1 | 37 | 1.4 | |
| Missing | 59 | 7 | 166 | 6.1 | |
| R-ISS stage | <.001 | ||||
| I | 140 | 16.6 | 435 | 15.9 | |
| II | 129 | 15.3 | 437 | 15.9 | |
| III | 148 | 17.5 | 322 | 11.8 | |
| Missing | 427 | 50.6 | 1540 | 56.3 | |
| ECOG PS | .903 | ||||
| 0-2 | 534 | 63.3 | 1713 | 62.6 | |
| 3-4 | 22 | 2.6 | 78 | 2.8 | |
| Missing | 288 | 34.1 | 943 | 34.5 | |
| HRCA | |||||
| Any HRCA | 227 | 26.9 | 376 | 13.8 | <.001 |
| del(17 p) | 121 | 14.3 | 231 | 8.4 | <.001 |
| t(4;14) | 87 | 10.3 | 130 | 4.8 | <.001 |
| t(14;16) | 41 | 4.9 | 47 | 1.7 | <.001 |
| Non-HRCA | |||||
| del(13q) | 414 | 49.1 | 768 | 28.1 | <.001 |
| t(11;14) | 78 | 9.2 | 411 | 15 | <.001 |
| First-line therapy | <.001 | ||||
| PI + IMiD combination | 342 | 40.5 | 916 | 33.5 | |
| PI-based | 151 | 17.9 | 615 | 22.5 | |
| IMiD-based | 284 | 33.6 | 871 | 31.9 | |
| Other | 67 | 7.9 | 332 | 12.1 | |
| ASCT | 215 | 25.5 | 768 | 28.1 | .140 |
HRCA is defined as the presence of 1 of the following: del (17p), t4;14, or t14;16).
IgG, immunoglobulin G; IQR, interquartile range; PS, performance status.